Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/projekte/45-a-randomized-phase-3-trial-with-anti-pd-1-monoclonal-antibody-pembrolizumab-mk-3475-versus-placebo-for-patients-with-early-stage-nsclc-after-resection-and-completion-of-standard-adjuvant-therapy-pearls